Navigation Links
Advance Nanotech Reports First Quarter 2008 Financial Results
Date:5/19/2008

Company achieves four-fold revenue increase as broad corporate changes are

implemented

NEW YORK, May 19 /PRNewswire-FirstCall/ -- Advance Nanotech, Inc. (OTC Bulletin Board: AVNA) today reported financial results for its first quarter ended March 31, 2008. This quarter was the first, full fiscal period since the Company refocused its business model from managing the development of a portfolio of early-stage nanotechnologies to developing one technology within the portfolio that has extraordinary immediate and long-term commercial potential: the Owlstone chemical detection system. Highlights from the quarter include:

-- Commenced a realignment of operations to focus on the Owlstone

technology

-- Board approved Bret Bader as incoming CEO effective upon completion of

Owlstone Exchange Agreement

-- Achieved initial product orders and shipments for Lonestar and Owlstone

vapor generators

-- Awarded second patent from the U.S. patent office, bringing total

issued U.S. patents to two, with 17 pending by Owlstone Nanotech, Inc.

Added homeland security expert to its Board of Directors

"The chemical detection industry is a large, rapidly growing market that spans across many commercial sectors, including industrial process control, homeland security, environmental monitoring and healthcare. Owlstone has developed next generation chemical detection products that are based on patented and patent-pending, proprietary technology to port real-time detection capabilities onto a silicon chip. Having successfully concluded the development of the core sensor, we are now developing and shipping product to meet real-time chemical detection needs in a wide range of industries. Given the near completion of the Advance Nanotech restructuring, we are eager to take the reins and rigorously grow our opportunities with our unique chemical detection platform," commente
'/>"/>

SOURCE Advance Nanotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
2. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
3. Advanced Life Sciences Announces First Quarter 2008 Financial Results
4. Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
5. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
8. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
9. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
10. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
11. Human Genome Sciences Advances Oncology Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 1ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 3Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 1Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 2Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 11Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 12Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 13Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 14Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 15Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 16Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 17